Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871467 · ClinicalTrials.gov registry record · Phase 1
Sargramostim for Myeloid Dendritic Cell Deficiency
A Phase 1 study of Dendritic Cell Deficiency, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT01871467 is a Phase 1 study of Dendritic Cell Deficiency that has completed, run by Johns Hopkins University. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01871467, a Phase 1 study of Dendritic Cell Deficiency, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
Previous studies have demonstrated a deficiency of blood dendritic cells in patients with kidney disease that is associated with the development of viral infections after kidney transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell levels in patients with kidney disease in the hopes of developing new therapies to prevent viral infections after kidney transplantation.
Conditions Studied
Interventions
- DRUG Sargramostim
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01871467
The ClinicalTrials.gov registry entry for NCT01871467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dendritic Cell Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Sargramostim is the first listed.
NCT01871467 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01871467 about?
NCT01871467 is a clinical study titled "Sargramostim for Myeloid Dendritic Cell Deficiency". Previous studies have demonstrated a deficiency of blood dendritic cells in patients with kidney disease that is associated with the development of viral infections after kidney transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell levels in patients with kidn...
What is the current status of trial NCT01871467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2013-05. Estimated completion is 2014-06.
What conditions does trial NCT01871467 study?
This clinical trial studies the following conditions: Dendritic Cell Deficiency.
What interventions are being tested in trial NCT01871467?
The interventions under investigation include: Sargramostim (DRUG).
Who is sponsoring clinical trial NCT01871467?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01871467 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.